Company Profile

Orphagen Pharmaceuticals Inc (AKA:Orphagen Biotechnology)
Profile last edited on: 1/24/19      CAGE: 44GQ5      UEI: GNYKMU6R4H64

Business Identifier: Metabolic, immune, and inflammatory disease therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

11558 Sorrento Valley Road Suite 4
San Diego, CA 92121
   (858) 481-6191
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Orphagen is structured around discovering drug candidates for potential drug targets for which small molecule ligands—potential drug-like molecules--have yet to be identified. The firm's goal is to identify, characterize, and position a new class of drug so that pre-clinical and clinical development can be initiated with partners and/or outside sources of funding. The targets come from the nuclear receptor family of drug targets. On a per target basis, nuclear receptors are one of the most successful target classes known to the pharmaceutical industry. Receptors that have yet to be exploited by the pharmaceutical industry are called orphan nuclear receptors, and form Orphagen’s central focus. Orphagen concentrates on the early stages of small molecule drug discovery: screening, hit-to-lead, lead optimization and preclinical development. The firm reduces the risks of downstream drug development by characterizing pharmacologically active molecules in cellular and animal models of disease. By pursuing this strategy, Orphagen signed the first strategic partnership for a novel target for treatment of autoimmune disease, ROR-gamma, with Japan Tobacco. Merck, BMS, Pfizer, Amgen and J&J later signed partnerships with other small biotech companies at the same target. Orphagen has identified novel approaches to several orphan indications, including retinitis pigmentosa, Cushing’s syndrome and adrenocortical cancer. It is also pursuing preclinical work on a chronobiotic for treatment of mood disorders and Alzheimer’s disease. Other projects at an earlier stage involve targets for treatment of sickle cell anemia and gliobl

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency